Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$81,833.00-1.73%ETH$2,477.14-3.73%GOLD$4,165.50+0.20%OIL$91.08-0.45%
Smart Investors Daily
SID Premium
PY

NASDAQ · PYPD

PolyPid Ltd.

Healthcare · Biotechnology

$4.95

Down-$0.05 (-1.01%)

Updated Oct 8, 2026, 10:30 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
40.46M
P/E ratio
-1.48
Dividend yield
0.00%
52-week range
$3.06 – $5.73
Volume
115.1K
Avg. volume
80.67K

Price performance · PYPD

PYPD price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

PYPD closed at $4.95 after 21 trading sessions, down 4.81% for the selected period.

Last close
$4.95
Period change
-4.81%
Period low
$4.95
Period high
$5.45
Daily close
View OHLC price history
PYPD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$5.11$5.19$4.90$4.95115.1K
Oct 6, 2026$5.22$5.24$5.05$5.1386.56K
Oct 5, 2026$5.28$5.33$5.03$5.20102.02K
Oct 2, 2026$5.49$5.55$5.06$5.19168.31K
Oct 1, 2026$5.30$5.47$5.28$5.37118.78K
Sep 30, 2026$5.27$5.355$5.16$5.2747.39K
Sep 29, 2026$5.40$5.40$5.23$5.2966.04K
Sep 28, 2026$5.22$5.4299$5.1863$5.3176K
Sep 25, 2026$5.33$5.45$5.22$5.2244.77K
Sep 24, 2026$5.27$5.365$5.19$5.3660.46K
Sep 23, 2026$5.43$5.43$5.10$5.2769.13K
Sep 22, 2026$5.19$5.4644$5.19$5.45127.01K
Sep 21, 2026$5.22$5.345$5.12$5.1740.76K
Sep 18, 2026$5.06$5.30$5.06$5.2166.36K
Sep 17, 2026$5.25$5.34$5.03$5.03104.97K
Sep 16, 2026$5.15$5.22$5.00$5.2176.49K
Sep 15, 2026$5.32$5.33$5.03$5.1681.67K
Sep 14, 2026$5.18$5.35$5.14$5.33180.69K
Sep 11, 2026$5.20$5.24$5.04$5.15100.18K
Sep 10, 2026$5.20$5.3816$5.13$5.1669.65K
Sep 9, 2026$5.22$5.39$5.16$5.20141.58K

Latest PYPD news

The latest Smart Investors Daily articles mentioning PYPD.

Stock researchCompany · Overview

PYPD research

Overview

Company profile and research snapshot.

Company profile

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$9.00
Implied upside
—
Analysts
10
PYPD recent ratings
DateFirmRatingTarget
Jul 21, 2026HC Wainwright & Co.Buy—
Feb 11, 2026HC Wainwright & Co.Buy—
Nov 13, 2025Roth CapitalBuy—
Aug 14, 2025Craig-HallumBuy—
Aug 13, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀

PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month Validation confirms that the application is complete and EMA initiates formal review of D-PLEX₁₀₀ D-PLEX₁₀₀ NDA concurrently under FDA Priority Review with November 28, 2026 PDUFA goal date PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness,

Yahoo · Oct 1, 2026

PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities

PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe. As a result, the exclusive European commercialization rights for D-PLEX₁₀

Yahoo · Sep 15, 2026

PolyPid Announces Participation in Upcoming Fall Investor Conferences

PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences: 5th Annual ROTH Healthcare Opportunities ConferenceDates: September 29, 2026Location: Metropolitan Club, New York, NYFormat: Panel discuss

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By